TAC1 and Parkinson disease: Moreover, the response of fiscalins A-C [11] and (−)-spiroquinazoline [12] (Figure 1A) as substance P inhibitors was also reported as a novel neuroprotective therapy in the intrastriatal 6-hydroxydopamine model of early stage of Parkinson’s disease (PD) [13].